The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Share News (HEMO)

Share Price Information for Hemogenyx (HEMO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.515
Bid: 1.50
Ask: 1.55
Change: 0.00 (0.00%)
Spread: 0.05 (3.333%)
Open: 1.515
High: 0.00
Low: 0.00
Prev. Close: 1.515
HEMO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

SMALL-CAP WINNERS & LOSERS: HeiQ drops on expectation of lower sales

Wed, 04th Jan 2023 10:36

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Wednesday.

----------

SMALL-CAP - WINNERS

----------

Hemogenyx Pharmaceuticals PLC, up 8.5% at 1.60 pence, 12-month range 1.05p - 2.12p. Completes its second process qualification run of the end-to-end process for the manufacture of HEMO-CAR-T cells. This was followed by analytical release tests to verify the quality of the manufacturer HEMO-CAR-T cells. The biopharmaceutical firm explains this run is the second of a minimum of three identical manufacturing runs needed for the submission of an investigational new drug application to the US Food & Drug Administration. The application is needed to gain authorisation from the US FDA to begin phase one clinical trails for HEMO-CAR-T cells.

----------

SMALL-CAP - LOSERS

----------

HeiQ PLC, down 53% at 26.00 pence, 12-month range 24.10p - 109.41p. Says its sales in the fourth quarter of 2022 were impacted by a "significant" deterioration in consumer demand as a result of worsening macroeconomic conditions. The textiles technology firm adds this reduction in sales has also been compounded by brands increasing their levels of inventory to all-time highs after the pandemic, due to persisting supply chain concerns. Consequently, HeiQ's customer base sees around 70% less demand in the final quarter of 2022. In addition, sales in China especially suffer due to pandemic related lockdowns. HeiQ now expects revenue for the year to be 20% below market expectations at between USD54 million and USD55 million. The firm's pretax loss is expected between USD2.5 million and USD3.5 million.

----------

By Heather Rydings, Alliance News senior economics reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
13 Jul 2020 18:25

UK TRADING UPDATE SUMMARY: Mineral & Financial Invests In Ideon Tech

UK TRADING UPDATE SUMMARY: Mineral & Financial Invests In Ideon Tech

Read more
30 Jun 2020 17:07

UK DIRECTOR DEALINGS SUMMARY: TalkTalk Telecom Chair Pays GBP860,000

UK DIRECTOR DEALINGS SUMMARY: TalkTalk Telecom Chair Pays GBP860,000

Read more
26 Jun 2020 14:50

IN BRIEF: Hemogenyx Inks Investigation And Material Supply Deal

IN BRIEF: Hemogenyx Inks Investigation And Material Supply Deal

Read more
15 Jun 2020 17:54

IN BRIEF: Hemogenyx To Take Next Steps In Developing Virus Treatment

IN BRIEF: Hemogenyx To Take Next Steps In Developing Virus Treatment

Read more
2 Jun 2020 12:57

UK TRADING UPDATE SUMMARY: Novacyt Virus Test Orders At EUR135 Million

UK TRADING UPDATE SUMMARY: Novacyt Virus Test Orders At EUR135 Million

Read more
12 May 2020 18:09

Hemogenyx Pharma Placing Raises GBP2.5 Million To Fund Studies

Hemogenyx Pharma Placing Raises GBP2.5 Million To Fund Studies

Read more
1 May 2020 11:18

UK EARNINGS SUMMARY: InfraStrata Targets Breakeven At Titanic Shipyard

UK EARNINGS SUMMARY: InfraStrata Targets Breakeven At Titanic Shipyard

Read more
22 Apr 2020 15:40

UK TRADING UPDATE SUMMARY: BATM Gets EUR29 Million Ventilator Order

UK TRADING UPDATE SUMMARY: BATM Gets EUR29 Million Ventilator Order

Read more
22 Apr 2020 06:55

Hemogenyx Approved For And Issued Hu-PHEC Patent In Europe

Hemogenyx Approved For And Issued Hu-PHEC Patent In Europe

Read more
20 Feb 2020 15:15

Hemogenyx Reports Positive Test Results From Cancer Therapy Treatment

Hemogenyx Reports Positive Test Results From Cancer Therapy Treatment

Read more
11 Feb 2020 12:00

Hemogenyx Gets US Patent For Postnatal Hemogenic Endothelial Cells

Hemogenyx Gets US Patent For Postnatal Hemogenic Endothelial Cells

Read more
30 Jan 2020 15:47

Hemogenyx Raises GBP648,200 To Continue T Cell Therapy Development

Hemogenyx Raises GBP648,200 To Continue T Cell Therapy Development

Read more
15 Jan 2020 13:23

Hemogenyx Shares Jump On Promising Data From Blood Cancer Therapy

Hemogenyx Shares Jump On Promising Data From Blood Cancer Therapy

Read more
18 Nov 2019 11:51

Hemogenyx CDX Antibody Treatment Potentially "Life-Saving"

Hemogenyx CDX Antibody Treatment Potentially "Life-Saving"

Read more
23 Oct 2019 10:43

Hemogenyx signs another deal with unnamed global pharma company

(Sharecast News) - Biopharmaceutical group Hemogenyx Pharmaceuticals announced on Wednesday that its wholly-owned subsidiary Immugenyx has entered into a research agreement with a global pharmaceutical company.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.